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ABSTRACT
Objectives To assess the long- term effects of 
arthroscopic partial meniscectomy (APM) on the 
development of radiographic knee osteoarthritis, and on 
knee symptoms and function, at 5 years follow- up.
Design Multicentre, randomised, participant- and 
outcome assessor- blinded, placebo- surgery controlled 
trial.
Setting Orthopaedic departments in five public 
hospitals in Finland.
Participants 146 adults, mean age 52 years (range 
35–65 years), with knee symptoms consistent with 
degenerative medial meniscus tear verified by MRI 
scan and arthroscopically, and no clinical signs of knee 
osteoarthritis were randomised.
Interventions APM or placebo surgery (diagnostic 
knee arthroscopy).
Main outcome measures We used two indices of 
radiographic knee osteoarthritis (increase in Kellgren 
and Lawrence grade ≥1, and increase in Osteoarthritis 
Research Society International (OARSI) atlas 
radiographic joint space narrowing and osteophyte sum 
score, respectively), and three validated patient- relevant 
measures of knee symptoms and function (Western 
Ontario Meniscal Evaluation Tool (WOMET), Lysholm, 
and knee pain after exercise using a numerical rating 
scale).
Results There was a consistent, slightly greater risk 
for progression of radiographic knee osteoarthritis in 
the APM group as compared with the placebo surgery 
group (adjusted absolute risk difference in increase in 
Kellgren- Lawrence grade ≥1 of 13%, 95% CI −2% to 
28%; adjusted absolute mean difference in OARSI sum 
score 0.7, 95% CI 0.1 to 1.3). There were no relevant 
between- group differences in the three patient- reported 
outcomes: adjusted absolute mean differences (APM 
vs placebo surgery), −1.7 (95% CI −7.7 to 4.3) in 
WOMET, −2.1 (95% CI −6.8 to 2.6) in Lysholm knee 
score, and −0.04 (95% CI −0.81 to 0.72) in knee pain 
after exercise, respectively. The corresponding adjusted 
absolute risk difference in the presence of mechanical 
symptoms was 18% (95% CI 5% to 31%); there were 
more symptoms reported in the APM group. All other 
secondary outcomes comparisons were similar.
Conclusions APM was associated with a slightly 
increased risk of developing radiographic knee 
osteoarthritis and no concomitant benefit in patient- 
relevant outcomes, at 5 years after surgery.
Trial registration  ClinicalTrials. gov (NCT01052233 
and NCT00549172).
INTRODUCTION
Arthroscopic partial meniscectomy (APM) is one 
of the most common orthopaedic surgical proce-
dures; over half a million surgeries are performed 
annually in the USA, and 1.1 million APM surgeries 
were performed in the UK between 1997 and 
2017.1 2 Most procedures are performed in middle- 
aged and older patients.1 Proponents of APM 
point to improved knee pain and function and 
quality of life after surgery as evidence of its effi-
cacy. However, 13 trials, rigorously summarised in 
2017 in a clinical practice guideline3 based on two 
systematic reviews,4 5 provided strong evidence that 
APM offers, at best, only little short- to medium- 
term benefit for most patients with degenerative 
knee disease compared with sham surgery or non- 
surgical management.
Some clinicians argue that an untreated meniscus 
tear increases the risk of knee osteoarthritis (OA). 
However, evolving consensus—based on observa-
tional data—suggests that APM is associated with 
increased risk of progression of knee OA and subse-
quent need for “corrective” surgery (high tibial oste-
otomy or total knee replacement).6 7 The respective 
roles of the underlying degenerative process and the 
potential harmful effect of arthroscopic surgery are 
challenging to disentangle in the above noted study 
designs due to confounding by indication.8
The risk of serious complications within 90 days 
of APM is likely low (<0.3%).9 However, any indi-
cation of possible long- term harmful effect should 
raise concern, given APM is unlikely to confer 
substantial benefit. Thus, to study whether APM 
(resection of torn meniscus tear) per se accelerated 
or delayed development of knee osteoarthritis in 
patients with an arthroscopically- verified degener-
ative tear of the medial meniscus, we carried out 
a pre- registered 5 year follow- up of our placebo- 
surgery controlled FIDELITY trial (Finnish 
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Degenerative Meniscus Lesion Study).10 The second objective of 
this analysis was to assess the long- term efficacy of APM on knee 
symptoms and function.
PATIENTS AND METHODS
We conducted a multicentre, randomised, participant- and 
outcome assessor- blinded, placebo- surgery controlled effi-
cacy trial involving participants aged 35–65 years with knee 
symptoms over 3 months, consistent with degenerative medial 
meniscus tear and unresponsive to conventional conservative 
treatment, and no advanced knee osteoarthritis. Patients were 
recruited from five orthopaedic centres in Finland during the 
period from December 2007 through January 2012. All patients 
had a suspicion of a medial meniscus tear based on symptoms 
and clinical tests, a tear that was later verified on both MRI and 
knee arthroscopy. Patients with an obvious traumatic onset of 
symptoms or a recent history of a locked knee were excluded. 
On entering the study, participants were informed that they 
would be allowed to consider a reoperation ≥6 months after 
the procedure if they did not have adequate relief of symptoms.
All participants had a diagnostic knee arthroscopy and were 
then (during the same operation) assigned to either APM or 
placebo surgery. For the randomization, we used sequentially 
numbered, opaque, sealed envelopes prepared by a statistician 
with no involvement in the clinical care of participants in the 
trial. Randomization was performed in a 1:1 ratio with a block 
size of 4. Study site, age (35–50 years or 51–65 years), sex, and 
the absence or presence of minor degenerative changes on a 
radiograph (Kellgren- Lawrence grade 0 or 1, respectively) were 
used to stratify allocation.
The participants, all caregivers, and those assessing the 
outcomes were blinded to the treatment assignment. Participants 
completed questionnaires at 2, 6, 12, 24, 36, 48, and 60 months 
postoperatively. At the 24 and 60 month follow- up, participants 
had a standardised clinical examination performed by an inde-
pendent orthopaedic surgeon who was unaware of treatment 
allocation.
Our primary research questions—on the development of knee 
osteoarthritis (NCT01052233) and on the efficacy of APM on 
knee symptoms and function (NCT00549172)—were registered 
separately in the  ClinicalTrials. gov database.
We have previously published the trial protocol10 and 12 
and 24 month follow- up findings.11–13 The trial protocol was 
approved by the institutional review board of the Pirkanmaa 
Hospital District (R06157). The trial was conducted in accor-
dance with the Declaration of Helsinki. All participants gave 
written informed consent.
Interventions
Arthroscopic evaluation included recording the presence of intra- 
articular pathology (meniscus tears, loose bodies and characteri-
sation of lesions to the tibiofemoral and patellofemoral chondral 
surfaces) according to the International Cartilage Repair Society 
(ICRS) cartilage injury classification scale14 and the International 
Society of Arthroscopy, Knee Surgery and Orthopaedic Sports 
Medicine (ISAKOS) classification of meniscal tears.15
During the APM, the damaged and loose parts of the meniscus 
were removed with the use of arthroscopic instruments until 
solid meniscal tissue was reached, with preservation of as much 
of the meniscus as possible. No other surgical procedure was 
performed. For the placebo surgery, simulated APM mimicked 
the sensations and sounds of APM. Participants were kept in 
the operating room for the same amount of time required to 
perform APM.
In both the APM and the placebo surgery groups, postoper-
ative care was delivered according to a standard protocol. All 
participants received the same walking aids and instructions for 
the same graduated home- based exercise programme.
Radiographic outcomes
Initially, we registered an increase of one grade or more in the 
Kellgren and Lawrence knee osteoarthritis grading (dichoto-
mous outcome: Yes or No) as our only primary outcome for the 
assessment of radiographic knee osteoarthritis (NCT01052233). 
The Kellgren and Lawrence scale is a semi- quantitative instru-
ment (ordered categorical grades 0–4) to assess the severity of 
radiographic tibiofemoral knee osteoarthritis.16 Patients who 
had undergone an osteotomy or a total knee replacement during 
follow- up were considered to have progressed radiographically 
(dichotomous outcome: Yes). We recruited additional expertise 
on the assessment of knee osteoarthritis to our research group 
(ME and AT) before any longitudinal radiographic readings and 
data analysis were made, and we decided to include another 
primary outcome: radiographic progression based on the sum of 
marginal tibiofemoral osteophyte grades and tibiofemoral joint 
space narrowing grades (according to the atlas developed by the 
Osteoarthritis Research Society International (OARSI); contin-
uous outcome, hypothetical range 0–18). We documented our 
additional decisions in the trial statistical analysis plan.17 The 
OARSI atlas is a semi- quantitative instrument (ordered categor-
ical grades 0–3) that assesses the severity of joint space narrowing 
and osteophytes, respectively, in knee osteoarthritis.18
All paired (baseline and 5 year) knee radiographs were initially 
read longitudinally by one experienced musculoskeletal radiol-
ogist (JK) who was blinded to treatment allocation and clinical 
data, and unblinded to the sequence of the radiographs. The 
reviewers of our statistical analysis plan17 recommended carrying 
out the analyses using two readers. We therefore recruited two 
new experienced musculoskeletal radiologists (NS and TK) to 
complete a new set of readings independently. The new readers 
were blinded to treatment allocation and clinical data, and 
unblinded to the time sequence of the radiographs. The readers 
initially met in person to calibrate their interpretation of grades 
on a test dataset before scoring the trial images independently. 
Any disagreements were resolved by consensus for all images 
(outcomes).17
Patient-relevant outcomes
To assess the efficacy of APM on knee symptoms and function 
(NCT00549172), our primary outcomes were the Western 
Ontario Meniscal Evaluation Tool (WOMET), the Lysholm knee 
score, and knee pain after exercise, all at 60 months after surgery. 
The WOMET19 is a meniscus- specific health- related quality- of- 
life instrument (HRQoL), validated specifically for patients with 
a degenerative meniscal tear.20 The Lysholm knee score is a vali-
dated, condition- specific outcome measure.21 22 WOMET and 
Lysholm scores each range from 0 to 100, with 0 indicating the 
most severe symptoms and 100 indicating the absence of symp-
toms. Knee pain after exercise (during the preceding week) was 
assessed on an 11- point numerical rating scale (NRS) ranging 
from 0 (no pain) to 10 (extreme pain).
As secondary outcomes, we (1) assessed the frequency of 
patients in the two treatment groups who did not have adequate 
relief of symptoms and whose treatment- group allocation was 
therefore unblinded (‘unblindings’), (2) queried the presence of 
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mechanical symptoms using the locking domain question of the 
Lysholm knee score,21 (3) assessed satisfaction and improvement, 
(4) registered serious adverse events, and (5) assessed develop-
ment of knee osteoarthritis according to the American College of 
Rheumatology (ACR) Clinical Criteria (dichotomous outcome: 
Yes or No).23 To assess mechanical symptoms, we asked patients 
to choose which of the following best reflected the status of 
their knee: (i) no locking or catching, (ii) catching sensations 
but no locking, (iii) occasional locking, (iv) frequent locking, or 
(v) locked at present. For satisfaction, participants responded 
to the following questions: “Are you satisfied with your knee 
at present?” and “Is your knee better than before the interven-
tion?” on a 5- point Likert scale. We classified “Very satisfied” 
or “Satisfied” as satisfied, and “Neither satisfied nor dissatis-
fied”, “Dissatisfied” and “Very dissatisfied” as dissatisfied.24 For 
improvement, we considered the responses “Much better” and 
“Better” to indicate improvement, and “Unchanged”, “Worse” 
or “Much worse” to indicate no improvement.
Blinded data interpretation
We interpreted the results of the trial according to a blinded 
data interpretation scheme.25 As two members of the Writing 
Committee (RS and PT) had previous access to the data, they 
recused themselves from making any interpretations. A statisti-
cian provided the Writing Committee with blinded results from 
the analyses, with the two arms labelled A and B. The Writing 
Committee then considered the interpretation of the results until 
a consensus was reached and agreed in writing on all alternative 
interpretations of the findings. We recorded the minutes of this 
meeting (online supplementary appendix 1), which was signed 
by all members of the Writing Committee. After agreement was 
reached, the trial statistician revealed the randomisation code 
and the interpretation corresponding to the correct treatment 
allocation was chosen. The draft of the manuscript was then 
finalised.
Patient involvement
There was no active patient involvement in the design of the 
study or in the recruitment to, or conduct of, the study. One of 
the main outcome measures (the WOMET) was initially devel-
oped with a patient- centred approach. The items included in 
the final version of the questionnaire were those identified by 
patients to have the most significant impact on their quality of 
life.19 When the results of this 5 year follow- up are published, 
a lay information flyer with final results will be sent to the 
recruiting centres for dissemination to the trial participants.
Statistical methods
The trial was originally designed to ascertain whether APM 
was superior to placebo surgery for treating patients with knee 
pain and a degenerative meniscus tear. The study was designed 
to detect a minimal clinically important improvement in the 
WOMET and Lysholm scores (defined as improvements of at 
Figure 1 Study flowchart.
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least 15.5 and 11.5 points, respectively) and in the score for 
knee pain after exercise (improvement of at least 2.0 points), as 
described previously.10
Baseline characteristics were analysed with the use of descrip-
tive statistics. We used logistic regression to analyse the primary 
and secondary binary outcomes. The model was adjusted for the 
baseline randomisation stratification factors (age (35–50 years 
or 51–65 years), sex, and absence or presence of minor degen-
erative changes on a radiograph (Kellgren and Lawrence grade 
0 or 1)). To obtain adjusted risk differences from the logistic 
model, the method of standardisation was used.26 We did not 
adjust for study site in the logistic regression analysis due to the 
low number of participants in some centres and the anticipated 
sparse data. A sensitivity analysis including the study site as a 
covariate was performed.
We used linear regression to analysis the OARSI sum score, 
adjusted for randomisation stratification factors and baseline value 
of the sum score. For the primary analysis of the patient- relevant 
outcomes assessed at baseline, 2, 6, 12, 24, 36, 48, and 60 months 
we used a mixed linear regression model. Patient was included as 
random effect, and time point (2, 6, 12, 24, 36, 48, and 60 months), 
treatment arm (APM or placebo), time × treatment interaction, 
and randomisation stratification factors (age (35–50 years or 51–65 
years), sex, absence or presence of minor degenerative changes on a 
radiograph (Kellgren and Lawrence grade 0 or 1), and study centre) 
were included as fixed effects. The model was adjusted for baseline 
values of the respective outcome variable.
All statistical analyses were performed on an intention to treat 
basis. As the frequency of crossover was low (n=8), we did not 
perform a per- protocol analysis. For the structural outcomes, 
where five persons could not be analysed due to missing data, 
the analysis was performed on full analysis set27 (ie, according to 
intention to treat principle), excluding participants with missing 
data. All inferential results are reported with 95% confidence 
interval (95% CI). Stata 15 (StataCorp 2017, Stata Statistical 
Software: Release 15, College Station, TX: StataCorp LLC) was 
used for all statistical analyses.
RESULTS
Of the 205 eligible patients, 146 were randomised; 70 were 
assigned to APM and 76 to placebo surgery (figure 1). The 
baseline characteristics of the two groups were similar (table 1). 
At the 60 month follow- up, four participants (2.7%) were lost 
to follow- up (two not responding to contact attempts and two 
deceased), and one participant completed the questionnaires but 
did not attend a clinical visit. Of the four lost to follow- up, two 
participants were from the APM group and two participants 
were from the placebo surgery group.
At 5 years after surgery, 72% (48 of 67) in the APM group 
and 60% (44 of 74) in the placebo surgery group had at least 
one grade progression in radiographic tibiofemoral knee OA. 
The adjusted absolute risk difference was 13% (95% CI −2% to 






Sex     
  Female 28 (40) 29 (38)
  Male 42 (60) 47 (62)
Age (years) 52.1±6.9 52.0±7.2
Body mass index (kg/m2) 26.9±4.0 27.9±4.0
Duration of symptoms (months) 10 (3–50) 10 (3–47)
Kellgren- Lawrence grade*     
  0 18 (26) 25 (33)
  1 40 (57) 37 (49)
  2 12 (17) 14 (18)
  OARSI sum score† 1.9±1.2 1.7±1.3
Meniscal tests     
  Positive McMurray test‡ 16 (23) 15 (20)
  Pain provoked by forced flexion and 
compression
50 (71) 59 (78)
  Pain provoked by palpation at the joint line 63 (90) 74 (97)
  Symptoms of catching or locking 32 (46) 37 (49)
  WOMET score§ 56.4±17.3 52.8±18.1
  Lysholm score¶ 60.2±14.7 60.1±14.6
  Pain after exercise (VAS)** 5.8±2.0 6.1±2.0
Values are numbers (percentages), means±SD or medians (ranges).
*Kellgren and Lawrence scale is a radiographic classification of the severity of knee 
osteoarthritis. Grade 0 denotes no osteoarthritis, grade 1 possible osteoarthritis, 
and grade 2 mild osteoarthritis. Scoring based on a consensus reading of two 
experienced musculoskeletal radiologists blinded to treatment allocation and 
clinical data.
†The sum of marginal tibiofemoral osteophyte grades and tibiofemoral joint space 
narrowing (JSN) grades based on the atlas by the Osteoarthritis Research Society 
International (OARSI) (continuous outcome, hypothetical range 0–18).
‡Results of a McMurray test are positive if a “click” over the medial tibiofemoral 
joint line is felt by the examiner during flexion and extension of the knee under 
varus stress.
§The Western Ontario Meniscal Evaluation Tool (WOMET) contains 16 items 
addressing three domains: 9 items addressing physical symptoms; 4 items 
addressing disabilities with regard to sports, recreation, work, and lifestyle; and 3 
items addressing emotions. The score indicates the percentage of a normal score; 
therefore, 100 is the best possible score, and 0 is the worst possible score.
¶The Lysholm knee score is based on an eight- item questionnaire designed to 
evaluate knee function and symptoms in activities of daily living. Scores range from 
0 to 100; higher scores indicate less severe symptoms.
**Knee pain after exercise (during the preceding week) was assessed on a rating 
scale of 0 to 10, with 0 denoting no pain and 10 denoting extreme pain.
APM, arthroscopic partial meniscectomy; VAS, Visual Analogue Scale.
Figure 2 Change in OARSI sum score from baseline to 5 year follow- 
up in the APM (blank bars) and placebo surgery (dark bars) groups. The 
x- axis shows the difference between 5 year and baseline OARSI sum 
score, while the y- axis shows the percentage of participants with each 
change score, per treatment arm. The higher the bars are at the right 
end of the x- axis, the more participants with more advanced progression 
of OA (higher OARSI score). APM, arthroscopic partial meniscectomy; 
OA, osteoarthritis; OARSI, Osteoarthritis Research Society International.
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28%). The adjusted absolute difference in the OARSI sum score 
was 0.7 (95 CI % 0.1 to 1.3), with more progression in the APM 
group (figure 2). These findings remained essentially unchanged 
in a sensitivity analysis that included study site as a covariate.
Both groups reported sustained improvement in knee symp-
toms and function. There were no relevant between- group 
differences: adjusted absolute mean differences (APM vs placebo 
surgery), −1.7 (95% CI −7.7 to 4.3) in WOMET, −2.1 (95% 
CI −6.8 to 2.6) in Lysholm knee score, and −0.04 (95% CI 
−0.81 to 0.72) in knee pain after exercise, respectively (table 2 
and figure 3).
Eight participants (12%) in the APM group and eight (11%) 
in the placebo surgery group reported symptoms severe enough 
to result in unblinding of group allocation. In both groups, most 
participants were satisfied (78% in APM vs 84% in placebo 
surgery) and reported improvement (81% vs 88%, respectively) 
or return to normal activities (table 3). A higher proportion of 
the APM group reported mechanical symptoms (adjusted abso-
lute risk difference: 18%, 95% CI 5% to 31%).
No serious adverse events related to the trial interventions 
were observed during follow- up from 24 to 60 months.
DISCUSSION
APM was associated with a slightly increased risk of progres-
sion of radiographic knee osteoarthritis without any additional 
benefit on knee pain, other symptoms or function compared 
with placebo surgery.
Comparison with other studies
Concern about the possible detrimental ‘downstream’ effects 
of APM on knee cartilage was originally prompted by observa-
tional data suggesting that both a meniscal tear and prior APM 
were independent risk factors for radiographic osteoarthritis.28 29 
A registry- based observational cohort of patients who underwent 
APM lent further support to the contention that APM per se may 
increase the risk of OA.7 Most recently, two separate analyses of the 
MeTeOR (Meniscal Tear in Osteoarthritis Research) randomised 
trial comparing APM with exercise therapy for patients with knee 
osteoarthritis and a meniscal tear have been published. The first, 
reporting the progression of MRI- based osteoarthritis markers 
over the first 18 months, suggested that patients undergoing APM 
had greater advancement of osteoarthritis than those treated 
non- operatively.30 The second, a 5 year follow- up reporting both 
patient- reported outcomes and the incidence of total knee replace-
ments (TKR), found no between- group difference in knee pain or 
function, but a greater likelihood of TKR was observed (HR 2.0, 
95% CI 0.8 to 4.9) for participants randomised to APM, compared 
with those randomised to physical therapy.31 Of note, the as- treated 
analysis of these data suggested that those exposed to APM over the 
follow- up period had a fivefold increased risk of TKR as compared 
with those allocated to physical therapy (HR 4.9, 95% CI 1.1 to 
20.9). Given that these analyses were adjusted for baseline grade of 
osteoarthritis, it seems likely that the findings are not due to greater 
pre- APM radiographic severity. Another recently published 5 year 
follow- up of a randomised trial reported radiographic deteriora-
tion in 60% of patients in the surgery group and 37% in the non- 
surgery group (p=0.060).32 However, all this evidence is subject to 
considerable uncertainties, as the observational data are prone to 
confounding by indication while the trial data30 32 are hampered by 
high rates of crossover (around 25–30%) from non- operative treat-
ment to surgery during the follow- up and high loss to follow- up 
(around 30%).
Confounding by indication is likely to occur in observational 
studies when a particular intervention is linked to certain selec-
tion criteria that may be linked with the outcome of interest. For 
example, in an observational study looking into the effects of APM 
on progression of osteoarthritis, patients who have more severe 
symptoms, which may hypothetically be linked to faster structural 
progression, may be more likely to be selected for APM. Therefore, 
the observational study design might falsely lead investigators to 
conclude that APM is causing knee osteoarthritis.
Strengths of this study
The elementary difference between our FIDELITY trial and the 
other trials that have assessed the benefits of APM on patients 
with knee pain attributed to a torn meniscus is the randomised, 
placebo- surgery controlled efficacy trial design. A placebo 
comparison group is generally considered essential in surgical 
trials with subjective endpoints,33 as it enables one to distin-
guish between the treatment effect specifically attributable to 
the critical therapeutic element of surgery (here, resection of 
the torn part of the meniscus) and the profound non- specific 
(and placebo) effects related to the act of surgery in itself.34–37 A 
placebo comparator is also similarly advantageous in teasing out 
the respective roles of the underlying degenerative process and 
any potentially harmful effect of the surgical procedure.
Previous unblinded trials comparing APM to various non- 
operative therapies38–40 have reported high crossover rates from 
initial non- operative treatment to surgery. Crossovers have gener-
ally been attributed to persisting symptoms and thus interpreted as 
evidence in support of the superiority of APM over non- operative 
treatments. However, this interpretation is prone to biases. Patients 
and researchers may have disproportionate expectations of the 
benefits of different treatments. When patients are told at entry 
about the possibility of surgical treatment but then allocated to 
non- operative treatment, so called ‘failed opportunity’ may mean 






Between- group difference in
improvement from baseline
WOMET score* 84.3 (80.1 to 88.6) 84.6 (80.5 to 88.7) −1.7 (−7.7 to 4.3)
Lysholm knee score† 83.7 (80.3 to 87.1) 85.8 (82.6 to 89.0) −2.1 (−6.8 to 2.6)
Knee pain after exercise‡ 2.0 (1.5 to 2.6) 2.2 (1.6 to 2.7) −0.04 (−0.81 to 0.72)
Values are presented as means (95% CI).
*The Western Ontario Meniscal Evaluation Tool (WOMET) contains 16 items addressing three domains: 9 items addressing physical symptoms; 4 items addressing disabilities 
with regard to sports, recreation, work, and lifestyle; and 3 items addressing emotions. The score indicates the percentage of a normal score; therefore, 100 is the best possible 
score, and 0 is the worst possible score.
†The Lysholm knee score is based on an eight- item questionnaire designed to evaluate knee function and symptoms in activities of daily living. Scores range from 0 to 100; 
higher scores indicate less severe symptoms.
‡Knee pain after exercise (during the preceding week) was assessed on a rating scale of 0 to 10, with 0 denoting no pain and 10 denoting extreme pain.
APM, arthroscopic partial meniscectomy.
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patients with residual symptoms are less satisfied with their care and 
subsequently driven to seek surgery.41 The bias may also work in 
the opposite direction. The authors of the MeTeOR trial speculated 
that the fivefold increase in the risk of TKR for participants ulti-
mately treated with APM may due to the fact that participants who 
had APM were more familiar and comfortable with the process of 
undergoing surgery and may have been more inclined to select TKR 
when symptoms persisted.31 Knowledge about prior treatment may 
also have a subconscious influence on the outcome assessors or the 
surgeons assessing the severity of residual symptoms.
Limitations of this study
Regarding the concerns related to crossover in our trial, the 
frequency of unblindings due to persisting symptoms was similar 
in the APM and placebo surgery groups (11% and 12%, respec-
tively). The proportions of participants who accurately guessed 
whether they had undergone a placebo procedure was similar 
in the two groups.11 Crossovers still pose a risk of bias in this 
trial. Participants who crossed over from placebo surgery to 
APM were exposed to the potentially negative effects of APM, 
but remained in their primary allocation group for the statis-
tical analyses (according to the intention to treat principle). 
Therefore, crossovers may have biased the observed difference 
towards the null, and our risk estimates for developing knee 
osteoarthritis due to APM may be underestimated.
Radiographic assessment of knee osteoarthritis is inherently 
prone to uncertainty due to the subjective nature of the method.42 
The reviewers of our statistical analysis plan17 also raised concerns, 
and we asked two experienced musculoskeletal radiologists to 
read all radiographs. In our trial, consensus versus single reader 
yielded the same results, reassuring us that the main finding of our 
radiographic analyses—that APM led to a slightly increased risk 
of developing radiographic knee osteoarthritis—is robust (Online 
supplemental appendix 2). The acquisition protocol of the knee 
radiographs dictated that standardised and weightbearing, semi- 
flexed, bilateral digital radiographs were obtained.43 However, not 
all centres used a mechanical positioning device or fluoroscopy to 
fix the flexion angle. The flexion angle was not uniform across the 
whole sample and all time points, which means that minor changes 
in joint space width must be interpreted cautiously. The Kellgren 
and Lawrence scale and OARSI atlas are osteophyte- driven grading 
systems and, as such, are more resilient to variability in the assess-
ment of the joint space width. Possible confounding related to 
radiograph measures should be equally distributed between the 
treatment groups, and accordingly our estimates on the magnitude 
of the between group effects should be valid.
Conventional wisdom versus FIDELITY findings
Concerns44–46 have been expressed regarding the alleged limited 
generalisability of the FIDELITY trial.11–13 It is true that we 
excluded patients with a true ‘traumatic’ onset of symptoms, 
which is at odds with the conventional wisdom that ‘traumatic’ 
tears would be most suitable for surgical resection. However, 
patients with traumatic meniscal tears may not experience 
greater improvements in patient- reported outcomes after APM 
than patients with degenerative tears.47
Our trial has been criticised as being “selected” or not repre-
sentative of “usual APM patients”,48 and we agree. We carefully 
crafted our eligibility criteria to ensure we included patients 
who were most likely to benefit from APM. The efficacy design 
ensures that our estimates are generalisable: failure to find APM 
efficacious under these ‘ideal’ circumstances makes it less likely 
that effectiveness could be proven in routine settings.49–51
We have been criticised for recruiting patients with symptoms not 
attributable to a meniscal tear.46 In patients with a degenerative knee 
disease, knee symptoms are not necessarily attributable to meniscus 
tissue. Symptoms may originate from other processes or tissues 
such as bone marrow lesions.52 Our eligibility screening reflected 
the contemporary clinical approach to diagnosing meniscus tear: 
careful history, standardised clinical examination including all 
conventional meniscus provocation tests, standard imaging (x- rays 
and MRI), and arthroscopy to verify the tear.
The presence of mechanical symptoms (sensation of knee 
catching or locking) is commonly considered a valid indication 
Figure 3 Mean values with 95% confidence intervals in all three 
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for arthroscopic surgery.46 53–55 This assertion is premised on 
the rationale that these symptoms are due to a joint structure 
lodging between the gliding articular surfaces. However, our 
data (table 3) and a number of other studies show that middle- 
aged and older patients reporting the presence of mechanical 
symptoms represent particularly poor candidates for APM.56–58 
Arthroscopic surgery is indicated for patients with a true locked 
knee (inability to extend their knee fully) caused by certain 
types of meniscus tears (eg, bucket- handle tear). However, 
patients with a true locked knee represent a small subset of the 
cohort of middle- aged and older patients currently undergoing 
arthroscopic meniscal knee surgery.59
CONCLUSIONS AND POLICY IMPLICATIONS
APM was associated with potential harm in the form of a slightly 
increased risk of development of radiographic knee osteoarthritis 
and no concomitant benefit in knee pain, other symptoms or 
function.
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What are the findings?
 ► Arthroscopic partial meniscectomy (APM) provided no more 
benefit for knee symptoms or function than placebo surgery. 
Arthroscopic partial meniscectomy was associated with 
a slightly increased risk of developing radiographic knee 
osteoarthritis at 5 years after surgery.
How might it impact on clinical practice in the future?
 ► Despite robust evidence that APM offers no clinically- relevant 
benefits for middle aged and older patients with persistent 
knee pain, the procedure remains one of the most common 
orthopaedic surgeries.
 ► Our findings corroborate a body of evidence from 
observational studies and unblinded randomised controlled 
trials suggesting an increased risk of developing knee 
osteoarthritis after APM. We strongly encourage clinicians 
and patients to consider alternatives to APM for managing 
knee symptoms.





(n=74) Risk difference with 95% CI*
Treatment group unblinding 8 (12) 8 (11) 0.01 (−0.09 to 0.12)
Reoperations 7 (10) 8 (11) 0.00 (−0.11 to 0.10)
  Arthroscopy 4 (6) 7 (9) Not applicable
  HTO/TKR 3 (4) 1 (1) Not applicable
Satisfied patients 53 (78) 61 (84) −0.06 (−0.19 to 0.08)
Improved patients 55 (81) 64 (88) −0.07 (−0.19 to 0.05)
Returned to normal activities 53 (78) 54 (76) −0.02 (−0.16 to 0.12)
Serious adverse events† 0 0   
Mechanical symptoms 20 (29) 9 (12) 0.18 (0.05 to 0.31)
Clinical OA according to ACR criteria 5 (8) 6 (9) −0.01 (−0.09 to 0.08)
Missing data: Treatment- group unblindings: 0; Reoperations: 0; Satisfied: 5; Improved: 5; Returned to normal activities: 7; Mechanical symptoms: 4; Clinical OA: 9.
Descriptive values are numbers (percentage).
*Estimates derived from an adjusted logistic regression model using the method of standardisation to derive risk differences.
†There were no serious adverse events attributable to index surgeries between 24 and 60 months of follow- up. The only serious adverse event encountered was a knee infection 
after dental procedure in the APM group at 4 months after surgery.
ACR, American Colleague of Rheumatology; APM, arthroscopic partial meniscectomy; HTO, high tibial osteotomy; OA, osteoarthritis; TKR, total knee replacement.
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